Navigation Links
Meningitis Vaccine Seems to Work Like a Charm
Date:1/14/2009

Study finds it has led to a considerable reduction in infection rates,,

WEDNESDAY, Jan. 14 (HealthDay News) -- Rates of pneumococcal meningitis, a potentially life-threatening infection, have declined substantially since a new vaccine was introduced in 2000, a new study shows.

The declines have been seen not only in children given the vaccine but also in adults, suggesting a herd immunity effect, the researchers noted. To assess the effect of the vaccine, researchers from several universities analyzed surveillance data from 1998 to 2005 in eight states.

Overall, the number of cases of the disease dropped 30 percent in that time, but the effect on the very youngest and oldest was even more pronounced: Incidence decreased by 64 percent in those younger than 2 and by 54 percent in those older than 65.

"This vaccine has really had a very profound effect on the incidence of pneumococcal disease," said study co-author Dr. Nancy Bennett, a professor of medicine at the University of Rochester Medical Center, in New York. The report appears in the Jan. 15 issue of the New England Journal of Medicine.

The study goes beyond previous research in terms of looking at population groups as well as different forms of Streptococcus pneumoniae, which causes pneumococcal meningitis, an inflammation of the meninges, or membranes, surrounding the brain and spinal cord.

"This is a pretty comprehensive study looking at a number of different serotypes [groupings of bacteria within a family] and all age groups. It gets a nice survey of the population," said Jeffrey Cirillo, an associate professor of microbial and molecular pathogenesis at Texas A&M Health Science Center College of Medicine, in College Station. "It is only in eight states so it's not throughout the entire country, but it's probably the most comprehensive analysis, and no one else had looked at it over that long of a period."

The vaccine, known as Prevnar and made by Wyeth Pharmaceuticals, is part of the standard vaccination recommendation for children in the United States ages 2 to 23 months, as well as for children 24 to 59 months old who are at high risk for pneumococcal disease.

Since the vaccine came out in 2000, there have been a number of studies reporting on its effect on meningitis and blood infections.

"This is the first to focus specifically on meningitis," Bennett said.

There was a 73.3 percent decrease in the incidence of PCV7 serotype (bacteria types covered by the vaccine) in all age groups. Researchers also found declines in antibiotic-resistant serotypes not specifically targeted by the vaccine.

"There were small increases in the rates of meningitis caused by serotypes that are not included in the vaccine," Bennett noted. The study reported a 60.5 percent increase in cases of meningitis types not protected by the vaccine, but Bennett said that "even a 60 percent increase in something that doesn't happen much has a small effect overall."

The increases were "outweighed by the overall decrease in disease," she said.

However, she continued, "it is something that we need to closely observe and that will be addressed with vaccines that cover more serotypes."

Prevnar was developed by researchers at the University of Rochester, who sold the technology to Wyeth, according to a university spokesman. Several authors of the study, including Bennett, have received funding from Wyeth and other pharmaceutical companies.

Cirillo described the study results as "very promising."

"This is a pretty significant finding, especially the large impacts the vaccine has on serotypes it covers," he said. "And within the serotypes that were covered, the efficacy was up to about 90 percent," referring to certain groups that showed the incidence of pneumococcal meningitis decreasing by almost 93 percent. That's amazing."

More information

For more on pneumococcal vaccination, visit the U.S. Centers for Disease Control and Prevention.



SOURCES: Nancy Bennett, M.D., professor, medicine, University of Rochester Medical Center, Rochester, N.Y.; Jeffrey Cirillo, Ph.D., associate professor, microbial and molecular pathogenesis, Texas A&M Health Science Center College of Medicine, College Station, Texas; Jan. 15, 2009, New England Journal of Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. AUDIO from Medialink and the National Meningitis Association: Peak Season for Meningitis
2. NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis
3. UCAR weather forecasts aim to reduce African meningitis epidemics
4. Corticosteroids of Little Use Against Childhood Meningitis
5. Meningitis vaccine study gets £200,000 boost
6. Schedules Revised for Flu, Meningitis Vaccines
7. New Meningitis Vaccine Works in Infants
8. Steroid Fails to Ease Meningitis in Trials
9. Meningitis Shot Available, Effective Year-Round
10. Novel Vaccines Improve Potential for European Vaccines Manufacturers
11. Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Meningitis Vaccine Seems to Work Like a Charm
(Date:2/20/2017)... ... February 20, 2017 , ... Houston dentist , Dr. ... care at his office, Antoine Dental Center. Emergency dentistry encompasses many treatments for ... at risk for serious complications and often experience severe pain. Not only does ...
(Date:2/20/2017)... ... , ... Chuck E. Cheese’s® and Center for Autism and Related Disorders (CARD) ... Cheese’s locations throughout New England, New York and New Jersey to provide children with ... of visiting Chuck E. Cheese’s in a sensory-friendly environment. , After a successful ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that ... gift was facilitated by the Pepin Family Foundation. , “We greatly appreciate this ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be participating ... Exposition, the event will take place February 23-25, 2017 at the Calvin L. Rampton ... Booth #909 with three new ambulances on display. , “JEMS is ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... ... proven to result in better care, and MEDfx and the Delaware Health Information ... of Delaware. , As the nation’s first state-wide health information exchange, DHIN stores ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)...   AC Group Inc. , a leading company, ... in the PMS/EHR healthcare marketplace, will exhibit the 7 ... succeed in this ecosystem at HIMSS,17. ... from over 200 ACOs, compared and analyzed an ACO,s ... that are providing different pieces of Population Health technologies ...
(Date:2/18/2017)... , Feb. 17, 2017   Parker ... protecting the rights of victims injured by medical ... regulators to call for better reporting. Congress required ... Safety concerns involving power morcellators and duodenoscopes ... to investigate how hospitals report injuries and deaths ...
(Date:2/17/2017)... CINCINNATI , Feb. 17, 2017  Ethicon, ... Torax Medical, Inc., a privately held medical device ... Reflux Management System, a novel minimally invasive ... acquisition of Torax Medical will enable Ethicon to ... the anatomy-altering laparoscopic Nissen fundoplication surgical procedure. 1 ...
Breaking Medicine Technology: